This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Other ulcerative colitis기타 궤양성 대장염

Contents and key points
ItemDetails
A. Classification codesICD-10: K51.8 | Special Copayment Reduction: V131 (severe intractable disease, 5 years)
B. SynonymsNo synonyms (unclassified ulcerative colitis, ulcerative colitis of indeterminate extent)
C. Adult onsetAdult onset: possible - a UC phenotype not included in the existing classification (proctitis, left-sided, pancolitis); a residual code rarely used in clinical practice
1. HistorySee main text
2. CausesSee main text
3. GeneticsSee main text
4. General epidemiologySee main text
5. PathophysiologySee main text
6. SymptomsSee main text
7. SignsSee main text
8. ScreeningSee main text
9. DiagnosisSee main text
10. TreatmentSee main text
11. PrognosisSee main text
12. PreventionSee main text
13. ReferencesSee main text

1. History

The classification system of ulcerative colitis (UC) has continued to develop since clinical descriptions began in the late 19th century. In ICD-10, K51.8 (other ulcerative colitis) is a residual code for classifying other forms of UC that do not fall under K51.0 (pancolitis), K51.2 (proctitis), K51.5 (left-sided colitis), or K51.9 (unspecified). This code is mainly used for atypical distribution or special clinical situations, and may include transverse colitis, right-sided colitis, or UC with partial colonic involvement that is difficult to classify specifically.

Historically, the classification of the extent of UC lesions has been refined because of its clinical importance. In 1954, Truelove and Witts presented severity criteria for UC, and various endoscopic classification systems were developed afterward. The 2006 Montreal classification standardized the extent of UC as E1 (proctitis), E2 (left-sided), and E3 (pancolitis), but the K51 codes of ICD-10 include a more subdivided classification. K51.8 is a code of low clinical usage frequency, applied to atypical forms that do not fall under the three categories of the Montreal classification or to cases where classification is deferred.


2. Causes

The cause of K51.8 other ulcerative colitis is the same as that of general UC. It arises from the complex interaction of genetic predisposition, gut microbiome abnormality, mucosal immune dysregulation, and environmental factors. When the distribution is atypical (right-sided colon alone, transverse colon involvement, etc.), differentiation from Crohn disease is even more important. In some cases, drugs (NSAIDs, isotretinoin, etc.) can cause atypical colonic inflammation, and in these cases improvement is observed after stopping the causative drug. Atypical courses of infectious colitis, ischemic colitis, and radiation colitis are also included in the differential diagnosis.


3. Genetics

The genetic basis of atypical UC corresponding to K51.8 shares the same susceptibility loci as typical UC. Loci common to UC, such as HLA-DR2, IL-10, IL-23R, and ECM1, are expected to show associations in other forms of UC as well. Large-scale studies exploring specific genetic predisposition in UC with atypical distribution are still lacking. NUDT15 and TPMT gene polymorphisms are associated with the risk of azathioprine toxicity, and testing before treatment is recommended.


4. General epidemiology

Accurate epidemiologic data for K51.8 other ulcerative colitis are limited. In ICD-10 coding, K51.8 is a residual code with low frequency of use in clinical practice and is often not tabulated separately even in specialty databases. Applying typical UC epidemiology, the overall prevalence of UC is 100-200/100,000 by Western standards and 30/100,000 or more in Korea. Atypical UC that could be classified as K51.8 is estimated at less than 5% of all UC. Right-sided UC has a relatively lower risk of colorectal cancer than UC with left-sided colonic involvement, but regular surveillance is still necessary.


5. Pathophysiology

The pathophysiology of other ulcerative colitis is the same as that of typical UC. The continuous process of mucosal barrier dysfunction, innate immune activation by gut microbial antigens, Th2/Th9-biased adaptive immune response, neutrophil infiltration, and mucosal ulcer formation is expressed at atypical sites. What is distinctive in UC with atypical distribution is that inflammation in the cecal area ("cecal patch") may appear in about 5-10% of patients with left-sided colitis or proctitis, and this is understood as a discontinuous manifestation of UC rather than an independent lesion. This pattern could be classified as K51.8, but most experts classify it as left-sided colitis (K51.5) and record the cecal patch in the staging.


6. Symptoms

The clinical symptoms of K51.8 vary with the colonic segment involved and disease activity. Bloody diarrhea, abdominal pain (location depending on the involved segment), urgency, and systemic symptoms (fever, weight loss, fatigue) may appear. With right-sided colonic involvement, right lower quadrant pain is prominent and can be confused with Crohn disease or appendicitis. With transverse colon involvement, periumbilical pain is characteristic. The degree of systemic symptoms is proportional to the extent of involvement and disease activity.


7. Signs

In physical findings, the location of abdominal tenderness according to the involved segment is a feature that distinguishes it from other UC phenotypes. With right-sided colonic involvement, right lower quadrant or right abdominal tenderness appears. Blood tests show elevated CRP, ESR, and white blood cell count, and anemia, depending on activity. Fecal calprotectin is a sensitive marker of active inflammation. Endoscopy shows continuous mucosal inflammation with atypical distribution.


8. Screening

Screening of the general population is not recommended. In patients complaining of nonspecific abdominal pain, bloody diarrhea, or weight loss, evaluation for organic bowel disease is performed with fecal calprotectin and colonoscopy. When right-sided colonic involvement is suspected, total colonoscopy is essential, and the diagnosis may be missed with sigmoidoscopy alone. Small bowel evaluation (CT or MR enterography) may be needed to differentiate from Crohn disease.


9. Diagnosis

Total colonoscopy and tissue biopsy are the diagnostic standard. The K51.8 diagnosis has the character of a diagnosis of exclusion, made after identifying a form of UC that is not clearly included in any of K51.0, K51.2, K51.5, or K51.9. Crohn disease (skip lesions, ileal involvement, perianal lesions, granulomas) must be excluded. Infectious colitis, ischemic colitis, radiation colitis, collagenous colitis, and drug-induced colitis are also differentiated. When necessary, small bowel involvement is assessed with small bowel CT/MR enterography.


10. Treatment

Treatment follows the same stepwise approach as typical UC. Mild-to-moderate: oral mesalazine (2.4-4.8 g/day), with enemas added if needed. Moderate-to-severe: systemic steroids (prednisolone 40-60 mg/day). Refractory: immunosuppressants (azathioprine), biologics (infliximab, vedolizumab, ustekinumab), JAK inhibitor (upadacitinib). Surgery: total proctocolectomy (for refractory disease or complications). In UC with atypical distribution, the effect of topical therapy (enemas, suppositories) may be limited depending on the involved segment, so systemic treatment centered on oral agents is the main approach.


11. Prognosis

The prognosis of K51.8 varies with the extent of involvement and activity. Atypical UC shows a natural history similar to UC with typical distribution, but is characterized by a tendency toward delayed diagnosis and treatment. Progression to pancolitis, need for surgery, and colorectal cancer risk are at levels similar to UC overall. If differential diagnosis from Crohn disease is delayed, the direction of treatment changes and affects prognosis. Regular follow-up endoscopy and histopathologic reassessment are important for confirming the diagnostic classification and early detection of complications.


12. Prevention

Prevention of other ulcerative colitis is the same as for typical UC. Mesalazine maintenance treatment lowers the relapse rate, and regular follow-up endoscopy monitors changes in disease activity and extent. Surveillance endoscopy for colorectal cancer is performed from 8-10 years after diagnosis. In UC with atypical distribution, the differential diagnosis from Crohn disease is regularly reviewed, and specialist (gastroenterology) reassessment is performed when treatment response is poor or the clinical course is atypical. During immunosuppressive treatment, the vaccination schedule for infection prevention is followed.


13. References

  1. Rubin DT, Ananthakrishnan AN, Siegel CA, et al. ACG Clinical Guideline: Ulcerative Colitis in Adults. Am J Gastroenterol. 2019;114(3):384-413. DOI: 10.14309/ajg.0000000000000152.
  2. Magro F, Gionchetti P, Eliakim R, et al. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. J Crohns Colitis. 2017;11(6):649-670. DOI: 10.1093/ecco-jcc/jjx008.
  3. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease. Can J Gastroenterol. 2005;19(Suppl A):5A-36A. PMID: 16151544.
  4. Kobayashi T, Siegmund B, Le Berre C, et al. Ulcerative colitis. Nat Rev Dis Primers. 2020;6(1):74. DOI: 10.1038/s41572-020-0205-x.
  5. Ordás I, Eckmann L, Talamini M, et al. Ulcerative colitis. Lancet. 2012;380(9853):1606-1619. DOI: 10.1016/S0140-6736(12)60150-0.
  6. Feuerstein JD, Isaacs KL, Schneider Y, et al. AGA Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative Colitis. Gastroenterology. 2020;158(5):1450-1461.
  7. Fumery M, Singh S, Dulai PS, et al. Natural History of Adult Ulcerative Colitis in Population-based Cohorts. Clin Gastroenterol Hepatol. 2018;16(3):343-356.
  8. Lamb CA, Kennedy NA, Raine T, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019;68(Suppl 3):s1-s106.
  9. Vernier-Massouille G, Balde M, Salleron J, et al. Natural history of pediatric Crohn's disease: a population-based cohort study. Gastroenterology. 2008;135(4):1106-1113.
  10. Peyrin-Biroulet L, Sandborn W, Sands BE, et al. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE). Am J Gastroenterol. 2015;110(9):1324-1338.